BD Launches New IV Medication Safety Solution, Helping Improve Patient Safety
BD Showcases Solutions and Technologies to Improve Patient Safety Across the Continuum of Care at #EAHP2017

CANNES, March 22, 2017 - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medication technology company, announced today the availability of its new IV Medication Safety Solution, designed to help to measurably prevent IV medication administration errors. This announcement was made at the European Association of Hospital Pharmacists (EAHP) congress, being held in Cannes, France March 22-24.

IV medication errors are a serious health care issue.1 They can occur at any stage of the medication delivery process, from prescription to administration2 and those occurring at the administration stage are the hardest to intercept.3 Their impact depends on the route of administration, type of drug and patient characteristics.4-8 In particular, intravenous (IV) infusions are identified as frequent contributors to medication errors and patient injuries that result from them.9-11 Clinical burden associated with infusion administration errors is suggesting potentially serious consequences for the patient in up to 29 percent of all observed infusions.11-16

BD provides advanced IV medication safety solutions, through helping to standardise drug library protocols with the Alaris™ Editor, to protect the patient with Alaris™ Plus Pumps with Guardrails™ Safety Software, and to evaluate IV medication errors and clinical practice using the Alaris™ CQI Reporter software and clinical services.

To take a step further in patient safety, BD today is launching the Alaris™ Communication Engine Platform, an enterprise IT software platform providing automated centralised management of all connected infusion devices. This system enables remote networked updates to the hospital drug library without interrupting the patient's infusions, collecting rich and actionable continuous quality improvement (CQI) data and centralising infusion pump device management.

The Alaris™ Communication Engine Platform is a key accelerator to BD's IV Medication Safety Solution, demonstrating proven results helping to improve medication errors reduction17-20 and cost associated to such errors18 while providing continuous quality improvement.17-20

"As we continue to provide innovative thinking to address the unmet needs in the area of medication management, BD recognises the growing contributions of connectivity," said Fernand Goldblat, vice president and general manager of Medication Management Solutions Infusion business for BD Europe. "With our IV Medication Safety Solution, BD can assist in creating a safer medication management process for patients while decreasing costs related to preventable adverse events. This addition to our leading Alaris™ technologies portfolio exemplifies our commitment to transform infusion solutions by making them simpler, seamless and connected.

"This latest development, enhances BD's End-to-End IV Safety capabilities within the Medication Management Solutions portfolio, comprised by the following elements:

  • Medication Management Innovation:
    • Through this unique "one partner" approach, BD is the only company that can offer health systems a holistic approach to manage medications throughout admissions, preparation and dispensing. This approach has the power to simplify and streamline medication management processes across the continuum of care. This further advanced for example, by RowaTM Dose which allows Hospitals to receive individualised medication's barcoded pouches both for acute and/or long term patients.
  • Medication Availability:
    • BD technologies help ensure that the right medication is available when and where needed to improve outcomes and cost-efficiency across the continuum of care. By enabling enterprise-wide medication management and analytics for all medications, BD solutions can improve and automate medication orders and delivery, including IVs and controlled substances.
  • End-to-End IV Safety:
    • BD offers clinically proven solutions to help minimise drug management risks while remaining continuously focused on improving and enhancing safety throughout medication management process: from initial compounding to administration at patient's bedside, including today's IV Medication Safety Solution announcement.

Where to find BD at EAHPTo learn more about BD's IV Medication Safety Solution and Medication Management solutions portfolio, including Rowa™Dose, visit BD booth #81 and participate in our satellite symposium:

Learn the importance of decreasing preventable errors throughout different stages of the medication management workflow, optimizing efficiency and reducing risk of exposure to hazardous drugs during preparation.

 

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of healthcare by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for healthcare providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to healthcare. In 2017, BD welcomed C. R. Bard and its products into the BD family. For more information on BD, please visit bd.com

For more information on BD, please visit bd.com.

Matthew Coppola

201 847 7370
Email

Monique N. Dolecki

201 847 5378
Email

 

References
  1. Valentin A, Capuzzo M, Guidet B, Moreno R, Metnitz B, Bauer P, et al. Errors in administration of parenteral drugs in intensive care units: multinational prospective study. BMJ 2009;338:b814.
  2. Stanhope N, Vincent C, Taylor-Adams SE, O'Connor AM, Beard RW. Applying human factors methods to clinical risk management in obstetrics. Br J Obstet Gynaecol 1997 Nov;104(11):1225-32.
  3. Pepper GA. Errors in drug administration by nurses. Am J Health Syst Pharm 1995 Feb 15;52(4):390-5.
  4. Gazarian M, Graudins LV. Long-term reduction in adverse drug events: an evidence-based improvement model. Pediatrics 2012 May;129(5):e1334-e1342.
  5. Hadaway LC. Managing i.v. therapy: "high-alert" drugs keep nurse managers ever watchful. Nurs Manage 2000 Oct;31(10):38-40.
  6. Hadaway LC. Managing i.v. therapy: "high-alert" drugs keep nurse managers ever watchful. Nurs Manage 2000 Oct;31(10):38-40.
  7. Kaushal R, Bates DW, Landrigan C, McKenna KJ, Clapp MD, Federico F, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA 2001 Apr 25;285(16):2114-20.
  8. Sullivan JE, Buchino JJ. Medication errors in pediatrics--the octopus evading defeat. J Surg Oncol 2004 Dec 1;88(3):182-8.
  9. Verklan MT. Malpractice and the neonatal intensive-care nurse. J Obstet Gynecol Neonatal Nurs 2004 Jan;33(1):116-23.
  10. Husch M, Sullivan C, Rooney D, Barnard C, Fotis M, Clarke J, et al. Insights from the sharp end of intravenous medication errors: implications for infusion pump technology. Qual Saf Health Care 2005 Apr;14(2):80-6.
  11. Kinnaeley E, Fishman G, Sims N, Cooper J, DeMonaco H. Infusion Pumps with "Drug Libraries" at the POint of Care - A Solution for Safer Drug Delivery. 2003. Chicago, IL, National Patient Safety Foundation.
  12. Narula P, Hartigan D, Puntis JWL. The frequency and importance of reported errors related to parenteral nutrition in a regional paediatric centre. e-SPEN 2011;6(3):e131-e134.
  13. Narula P, Hartigan D, Puntis JWL. The frequency and importance of reported errors related to parenteral nutrition in a regional paediatric centre. e-SPEN 2011;6(3):e131-e134.
  14. Deters M, Prasa D, Hentschel H, Schaper A. Iatrogenic intravenous medication errors reported to the PIC Erfurt Iatrogenic intravenous medication errors M. Deters et al. Clinical Toxicology 2009;47(2):169-73.
  15. Flaatten H, Hevrøy O. Errors in the intensive care unit (ICU). Experiences with an anonymous registration. Acta anaesthesiologica Scandinavica 1999;43(6):614-7.
  16. Walker CA, Oborne CA, Burmiston S, Thomas S. Use of failure severity and frequency to reduce insulin risk in secondary care. Clinical Pharmacist 2011;3(4):S4-S5.
  17. Pang RKY, Kong DCM, de Clifford JM, Lam SS, Leung BK. Smart infusion pumps reduce intravenous medication administration errors at an Australian teaching hospital. J Pharm Pract 2011;41(3):192-5.
  18. Westbrook JI, Woods A, Rob MI, Dunsmuir WT, Day RO. Association of interruptions with an increased risk and severity of medication administration errors. Arch Intern Med 2010 Apr 26;170(8):683-90.
  19. Kastrup M, Balzer F, Volk T, Spies C. Analysis of event logs from syringe pumps: a retrospective pilot study to assess possible effects of syringe pumps on safety in a university hospital critical care unit in Germany. Drug Safety 2012;35(7):563-74.
  20. Manrique-Rodríguez S, Sánchez-Galindo AC, Fernández-Llamazares CM, Calvo-Calvo MM, Carrillo-Álvarez Á, Sanjurjo-Sáez M. Safe intravenous administration in pediatrics: A 5-year Pediatric Intensive Care Unit experience with smart pumps. Medicina Intensiva 2016; 40(7):411-421
  21. Manrique-Rodríguez S, Sánchez-Galindo AC, López-Herce J, Calleja-Hernández MÁ, Martínez-Martínez F, Iglesias-Peinado I, Carrillo-Álvarez A, Sanjurjo-Sáez M, Fernández-Llamazares CM. Implementing smart pump technology in a pediatric intensive care unit: a cost-effective approach. Int J Med Inform. 2014 Feb;83(2):99-105.
  22. Sara Arenas Lopez, et al Safe implementation of standard concentration infusions in paediatric intensive care. Journal of Pharmacy and Pharmacology, 2016